Cannabis Science Inc (OTCMKTS:CBIS) showing jumped of 0.43% and closed at $0.0826, after gaining total volume of 0.00 shares. Its earnings per share (EPS) is -$0.01 and its beta value stands at -2.87 points and has total market capitalization of $191.00 million and a total of 2.31 billion outstanding shares.
Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phyto cannabinoid-based pharmaceutical products primarily in the United States. The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary